# Bristol-Myers Squibb Company  Share Price Target ‘$56.30’, now 11.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/bristol-myers-squibb-company-share-price-target-56.30-now-11.5-upside-potential/4121145305
- Published: 2024-02-29T13:42:27+00:00
- Author: Charlotte Edwards

**Bristol-Myers Squibb Company** with ticker code (BMY) have now 20 analysts in 
total covering the stock. The consensus rating is pointing to ‘hold’. The range 
between the high target price and low target price is between $85.00 and $41.00 
and has a mean share price target at $56.30. (at the time of writing). Given that
the stocks previous close was at $50.51 and the analysts are correct then there 
would likely be a percentage uptick in value of 11.5%. There is a 50 day moving 
average of $50.39 and the 200 day moving average is $56.97. The company has a market
cap of 102.97B. The current share price for the company is: $50.92 USD

 The potential market cap would be $114,773,428,839 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 13.19, revenue per share of $21.75
and a 5.63% return on assets.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged
in the discovery, development, licensing, manufacturing, marketing, distribution,
and sale of biopharmaceutical products. It offers products for a range of therapeutic
classes, which include oncology, immunology, cardiovascular and hematology. Its 
pharmaceutical products include chemically synthesized or small molecule drugs and
products produced from biological processes, called biologics. Biologics are administered
to patients through injections or by infusion. Its products include Revlimid, Abecma,
Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti,
Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline
of investigational medicines designed to target the common mutations associated 
with oncogenesis, including repotrectinib. Its products are sold to wholesalers,
distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

Share on: